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OBJECTIVES The aim of this project was to assess the utility of dobutamine stress echocardiography (DSE)
for evaluation of women with suspected ischemic heart disease.
BACKGROUND Most investigations addressing efficacy of diagnosis and treatment of coronary artery disease
(CAD) have been performed in predominantly male populations. As part of the Women’s
Ischemia Syndrome Evaluation (WISE) study, DSE was assessed in women participating at
the University of Florida clinical site.
METHODS Women with chest pain or other symptoms suggestive of myocardial ischemia and clinically
indicated coronary angiography were eligible for the WISE study. Enrolled subjects
underwent DSE using a modified protocol. Coronary stenosis was assessed by core laboratory
quantitative coronary angiography (QCA).
RESULTS The 92 women studied ranged in age from 34 to 82 years (mean 57.5). All women had $1 major
risk for CAD, and most (89, 97%) had $2 risk factors. In 78 women (85%), left ventricular wall
motion was normal at baseline and during peak infusion. The remaining 14 women had wall
motion abnormalities during DSE. By QCA, 25 women (27%) had $50% coronary stenosis,
including 10 with single-vessel obstruction. Dobutamine stress echocardiography was abnormal in
10 of these 25 women, yielding overall sensitivity of 40%, and 60% for multivessel stenosis.
Exclusion of women with inadequate heart rate response yielded overall sensitivity of 50%, and
81.8% for multivessel stenosis. Dobutamine stress echocardiography was normal in 54 of the 67
women with ,50% coronary narrowing, specificity 80.6%.
CONCLUSIONS Dobutamine stress echocardiography reliably detects multivessel stenosis in women with
suspected CAD. However, DSE is usually negative in women with single-vessel stenosis, and
in the larger subset without coronary stenosis. Ongoing protocols of the WISE study are
expected to improve diagnostic accuracy in women with single-vessel disease, as well as
provide important data in the substantial number of women with chest pain but without
epicardial coronary artery stenosis. (J Am Coll Cardiol 1999;33:1462–8) © 1999 by the
American College of Cardiology
Most investigations addressing efficacy of diagnosis and
treatment of coronary artery disease (CAD) have been
performed in predominantly male populations. It is now
recognized that the findings of these studies may not be
strictly applicable to women. For example, noninvasive tests
used for diagnosis of CAD in men have been reported to
yield inferior results in women, largely due to poor speci-
ficity (1–5). There is concern that these limitations of
testing and other ill-defined biases lead to delayed recogni-
tion of CAD in women, and hence may influence treatment
and prognosis (5–9).
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In response to these issues, the National Heart, Lung and
Blood Institutes initiated a project to assess the utility of
existing diagnostic tests as well as evaluate innovative
methods for the diagnosis of ischemic heart disease in
women. As part of this project, dobutamine stress echocar-
diography (DSE) was assessed in women participating in
the study at the University of Florida clinical site. This
article reports the findings of these studies during the pilot
phase of the Women’s Ischemia Syndrome Evaluation
(WISE).
METHODS
Women $18 years of age were enrolled in the WISE study
if they met the following criteria: 1) chest pain or other
symptoms suggestive of myocardial ischemia; 2) clinically
indicated coronary angiography (ANGIO), and 3) ability to
give informed, written consent. Criteria for exclusion in-
cluded 1) acute myocardial infarction or unstable angina in
the preceding 4 weeks; 2) uncontrolled systemic hyperten-
sion, defined as blood pressure .160/95 mm Hg on at least
two occasions; 3) severe heart failure defined as New York
Heart Association functional class IV; 4) coronary revascu-
larization within the previous six months; 5) noncardiac
conditions likely to influence outcome, and 6) factors related
to ability to comply with study protocol. The protocol was
approved by the University of Florida Institutional Review
Board, and each patient gave informed consent. From
November 1996 to May 1998, 944 patients were screened at
the University of Florida clinical site; 801 were excluded for
a variety of reasons. The most frequent reason for exclusion
(in 72%) was lack of clinical indication for ANGIO (as
determined by the referring physician) or refusal of ANGIO
by the patient. The remaining excluded patients expressed
disinterest in the study (23%), refused at the advice of their
referring physician (4%) or had miscellaneous other reasons
(1%).
Dobutamine stress echocardiography protocol. Dobut-
amine stress echocardiography was performed using a pro-
tocol modified for the WISE study. Subjects were instructed
to discontinue beta-adrenergic blocking agents, calcium
channel blocking agents and long-acting nitrates on the
evening before testing. Baseline images in standard views
were obtained and recorded on 0.5-in. (1.27 cm) videotape.
Dobutamine infusion was initiated at 5 mg/kg/min, and the
dosage increased at 5-min increments to 10, 20, 30 and
40 mg/kg/min. Intravenous atropine (0.25 to 1.0 mg) was
given after the 40-mg/kg/min dose if the target heart
rate (i.e., 85% predicted maximum) was not achieved.
Dobutamine infusion was terminated if any of the following
occurred: 1) target heart rate; 2) new segmental wall motion
abnormality or $2 mm ST segment depression; 3) complex
ventricular ectopy or sustained supraventricular tachycardia;
4) hypotension defined as $20 mm Hg decrease from
baseline systolic blood pressure and absolute pressure
,90 mm Hg, or hypertension defined as systolic blood
pressure $220 mm Hg; 5) severe chest pain, and 6)
intolerable symptoms (e.g., dyspnea, nausea). Images at
baseline, 5 mg/kg/min, peak and recovery were digitized in
continuous loop and displayed in quad loop format using a
commercially available on-line digitizing system (Hewlett-
Packard Sonos 1000 model 77025A, Andover, Massachu-
setts, upgraded with Nova MicroSonics High Performance
Acquisition Module, Mahwah, New Jersey), and were also
recorded on videotape. A 12-lead electrocardiogram (ECG)
was recorded at baseline, at the end of each 5-min stage and
at recovery. The ECG, blood pressure (DynaMap, Tampa,
Florida) and echocardiographic images were monitored
throughout the procedure.
Wall motion analysis was performed by a single cardiol-
ogist experienced in interpretation of DSE studies and
masked to clinical and ANGIO findings. Interpretation was
performed from the digitized images, and videotaped im-
ages were reviewed only for clarification of questionable
findings. For analysis, the left ventricle was divided into 16
segments as recommended by the American Society of
Echocardiography (10). Segments were graded based on
systolic thickening and excursion: 1 5 normal; 2 5 hypo-
kinetic; 3 5 akinetic; 4 5 dyskinetic. Wall motion score
index was calculated as the total score (sum of grades of all
segments) divided by the number of segments scored. An
ischemic response to dobutamine infusion was considered
present when the score in any segment increased with the
exception of akinetic to dyskinetic. Abnormal segmental
wall motion at baseline or peak infusion was considered
indicative of CAD. Wall motion of basal left ventricular
segments supplied by the posterior coronary circulation was
interpreted as abnormal only when visualized in two echo-
cardiographic views. Dobutamine stress echocardiography
studies were further categorized as normal if no abnormality
was observed at baseline or peak stress and target heart rate
was achieved, abnormal if wall motion abnormality was
present at baseline or developed at peak stress or indeter-
minate if no abnormality was observed at baseline or peak
stress and target heart rate was not reached.
Observer variability of wall motion analysis at the Uni-
versity of Florida was established before initiation of the
project by interpretation of 25 DSE studies by two experi-
enced cardiologists. Intraobserver agreement for the WISE
investigators was 90%, that is, exact grade for specific
segments read on two separate occasions. Interobserver
agreement on segment grades by the two cardiologists was
Abbreviations and Acronyms
ANGIO 5 coronary angiography/angiographic
CAD 5 coronary artery disease
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85%. Discrepancies in wall motion score .1 grade occurred
in only 2% of segments.
Coronary angiography protocol. Cardiac catheterization
was performed using standard clinical techniques. Coronary
angiography was performed using the WISE study protocol.
Multiple projections of the left and right coronary arteries
were recorded with particular care taken to achieve adequate
opacification and visualization of proximal and middle
portions of each coronary artery without overlapping or
distortion. Images were recorded on 35-mm film at $30
frames per second. All films were interpreted by the WISE
Angiography Core Laboratory without knowledge of clin-
ical or DSE findings using previously published methods
(11). Briefly, all angiograms were first reviewed for quality,
and only those graded satisfactory or superior were further
analyzed. These angiograms were then analyzed qualita-
tively for the presence or absence of lumen outline irregu-
larities. Arteries with irregularities that reduce the lumen
diameter (measured by electronic calipers) $20% were
considered to have coronary artery stenosis. Stenoses were
further classified as minimal (20% to 49% narrowing),
moderate (50% to 69%) or severe ($70%). An angiography
severity score which incorporates percent luminal, extent
and location of stenosis as well as the presence of collaterals
was also calculated (11). A severity score of 5.0 was assigned
to angiograms with only minor irregularities reducing the
lumen diameter #20%; larger scores indicate increasing
severity of angiographic disease.
Statistical methods. Continuous variables were summa-
rized as mean 6 SD. Sensitivity of DSE was calculated as
the number of abnormal tests divided by the number of
subjects with significant ($50%) coronary stenosis; speci-
ficity was calculated as the number of normal tests divided
by the number of subjects without significant coronary
stenosis. Comparisons among patient groups (i.e., those
with normal, abnormal and indeterminate DSE) were made
using chi-square or Fisher exact tests for categorical vari-
ables, and Kruskal-Wallis rank-sum tests for ordinal and
continuous variables such as number of CAD risk factors
and age. McNemar test was used to compare the accuracy of
wall motion score, chest pain and ST segment changes,
alone and in combination, during DSE. Statistical signifi-
cance was considered present at p , 0.05.
RESULTS
Patient population. A total of 143 women met all criteria
for inclusion. Of these, 51 women were excluded for a
variety of reasons: inadequate acoustic window (15 subjects),
test cancellation by referring physician because of perceived
contraindication (4 subjects), tenderness at mastectomy site
(1 subject), refusal or withdrawal of consent (22 subjects),
failure to complete testing (4 subjects) and coronary angio-
plasty performed shortly after qualifying ANGIO (5 sub-
jects). The remaining 92 women completed DSE and
constituted the study population.
These 92 subjects were recruited from the cardiovascular
clinic (56%) or inpatient cardiology service (41%), or re-
ferred by the cardiology consultation service and emergency
department (3%). Chest pain was the most frequent indi-
cation for evaluation and was present in 83 women (90%).
The remaining nine women were referred for evaluation of
dyspnea or because of an abnormal exercise stress test. The
ages of the 92 women ranged from 34 to 82 years (mean
57.5). The majority (71, 77%) were white, 18 (20%) were
African-American and the remaining 3 (3%) were Hispanic
or Asian. All women had at least one risk factor for CAD
including age $65 years, tobacco use, hypertension, dyslip-
idemia, family history of CAD, postmenopausal status or
diabetes mellitus, and most (89, 97%) had two or more risk
factors (Table 1). Pretest probability of CAD in 77 women
(excluding 15 with history of myocardial infarction or
revascularization) was assessed based on age, gender and
symptoms (12). Probability was determined to be low
(,10%) in 5 (6.5%), moderate (10% to 80%) in 60 (77.9%)
and high (.80%) in 12 (15.6%). Subjects had taken a
variety of medications, including beta-blockers, calcium
channel blockers and angiotensin-converting enzymes in-
hibitors, before testing (Table 1). Although all subjects
complied with instructions to discontinue medications on
the evening before testing, 20 (24%) women had taken
beta-blockers within 24 h of DSE.
Dobutamine stress echocardiography. Reasons for termi-
nation of DSE included attainment of target heart rate (62
subjects, 67%), maximum infusion dose and administration
Table 1. Characterization of Women Undergoing Dobutamine
Stress Echocardiography (n 5 92)
Value (n)*
Age (yr) 57.5 6 10.1 (92)
Systolic BP (mm Hg) 136.8 6 22.2 (91)
Diastolic BP (mm Hg) 76.0 6 10.9 (91)
Current tobacco use 17 (18.7%) (91)
Hypertension 51 (56.0%) (91)
Dyslipidemia 52 (65.0%) (80)
Family history of CAD 55 (61.1%) (90)
Postmenopausal status 83 (90.2%) (92)
Diabetes mellitus 21 (23.1%) (91)
Prior revascularization (No., %) 6 (6.5%) (92)
Total cholesterol (mg/dl) 209.4 6 44.2 (52)
HDL (mg/dl) 48.0 6 14.8 (50)
LDL (mg/dl) 127.5 6 40.5 (44)
Triglycerides (mg/dl) 178.0 6 123.9 (52)
Hormone replacement therapy (No., %) 33 (36.7%) (90)
Beta-blockers (No., %) 27 (30.3%) (89)
Calcium channel blockers (No., %) 34 (38.2%) (89)
ACE inhibitors (No., %) 20 (22.5%) (89)
*Number of women with listed baseline data.
ACE 5 angiotensin-converting enzyme; BP 5 blood pressure; CAD 5 coronary
artery disease; HDL 5 high density lipoprotein; LDL 5 low density lipoprotein.
1464 Lewis et al. JACC Vol. 33, No. 6, 1999
Dobutamine Stress Echocardiography in Women May 1999:1462–8
of atropine without reaching target heart rate (8 subjects,
9%), anginal chest pain (15 subjects, 16%), new wall motion
abnormality (3 subjects, 3%), hypotension (3 subjects, 3%),
hypertension (4 subjects, 4%) and other intolerable symp-
toms such as dyspnea or extreme anxiety (8 subjects, 9%); 13
subjects (14%) had more than one reason for termination.
Two tests were terminated due to ventricular tachycardia or
sustained supraventricular tachycardia. Most women (70,
76%) received a maximum infusion rate 30 to 40 mg/kg/min
(mean dose 32.2 6 9.3); 22 (24%) also received atropine. A
variety of other symptoms were reported at peak stress, but
did not result in premature termination of DSE. These
symptoms included atypical chest pain 43 (47%), nausea 18
(20%) and lightheadedness 8 (9%). No symptoms were
reported in 31 (34%) subjects.
Wall motion analysis. The majority of women (78, 85%)
had normal left ventricular wall motion at baseline and
during peak dobutamine infusion. This included 64 women
who reached target heart rates, and 14 with studies consid-
ered “indeterminate” because of inadequate chronotropic
response; that is, target heart rates were not achieved. The
remaining 14 women had segmental wall motion abnormal-
ities during dobutamine infusion, seven of these with
baseline abnormalities. Data from these 14 women are
summarized in Table 2.
Relation of DSE to ANGIO findings. By quantitative
coronary angiography, 67 women (73%) had minimal or no
disease (,50% narrowing). The other 25 women (27%) had
moderate or severe narrowing ($50%) in one or more
coronary arteries. This included 10 women with single-
vessel, 10 with two-vessel and 5 with three-vessel obstruc-
tion. Of the 25 women with $50% coronary stenosis, 10
had abnormal DSE studies at peak infusion (Table 2). The
remaining 15 women had no wall motion abnormality at
baseline or peak stress; 10 of these reached target heart rate,
and five were considered indeterminate studies due to
inadequate chronotropic response (two of these five had
taken beta-blockers within 24 h of DSE). Thus, overall
sensitivity of DSE for detection of $50% coronary narrow-
ing was 40%, but was 60% in patients with two- or
three-vessel stenosis. Sensitivity of DSE in women without
baseline wall motion abnormality was 21% overall, and
33.3% in patients with two- or three-vessel disease. Analysis
of data with exclusion of women with indeterminate DSE
yielded overall sensitivity of 50%, and 81.8% for two- or
three-vessel stenosis; in women without baseline wall mo-
tion abnormalities, sensitivities were 28.6% overall and 60%
for multivessel disease. All cases of ANGIO stenosis in the
absence of segmental wall motion abnormality during DSE
occurred in the presence of single-vessel coronary narrow-
ing, ,70% stenosis or indeterminate studies due to inade-
quate chronotropic response (Table 3). Among the 14
women with indeterminate DSE studies, five (35.7%) had
significant coronary stenosis. In the 92 study subjects,
accuracy of DSE was 69.6%, with positive predictive value
of 71.4% and negative predictive value of 84.4%. Accuracy
of DSE was also assessed using a combination of other
potential markers of CAD including ischemic ST segment
changes and chest pain during dobutamine stress. No
significant improvement in accuracy was observed by com-
bination of these markers (p 5 0.48).
Coronary angiography severity score in the 67 patients
with no or minimal disease (coronary stenosis ,50%)
ranged from 5.0 to 24.0 (mean 6.7). Mean severity score in
the 25 patients with $50% coronary narrowing ranged from
8.8 to 78.5 (mean 28.7). Angiography severity score was
highest in women with abnormal DSE, lowest in women
Table 2. Wall Motion Score and Coronary Anatomy in Women With Abnormal Dobutamine
Stress Echocardiography
ID No.
Baseline
WMSI
Low dose
WMSI
Peak
WMSI
Angiography Findings, No.
(Vessels) >50% stenosis
Angiography
Severity Score*
30002 1.0 1.0 1.25 3 (lad, lcx, rca) 41.75
30006 1.5 1.37 1.50 2 (lad, lcx) 51.00
30008 1.0 1.0 1.25 2 (lad, rca) 23.75
30010 1.5 1.31 1.50 3 (lad, lcx, rca) 56.50
30011 1.0 1.0 1.25 1 (lad) 41.00
30031 1.0 1.0 1.19 0 5.00
30043 1.87 1.6 2.06 3 (lm, lad, rca) 78.50
30077 1.0 1.0 1.25 0 5.00
30114 1.19 1.19 1.44 2 (rca, lad) 27.75
30117 1.00 1.0 1.25 2 (lad, lcx) 27.75
30120 1.62 1.5 1.87 2 (lad, rca) 39.0
30122 1.50 1.37 1.62 3 (lad, rca, lcx) 56.0
30123 1.00 1.0 1.38 0† 24.0
30131 1.19 1.06 1.12 0 5.0
*Larger score is indicative of more extensive disease; see text for details. †Subject with 49% stenosis in right coronary artery.
lad 5 left anterior descending; lcx 5 left circumflex; lm 5 left main; rca 5 right coronary artery; WMSI 5 wall motion score
index (see text for details).
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with normal DSE and intermediate in those with indeter-
minate studies (Table 4). An angiography severity score of
$35.0 was always associated with abnormal DSE; a score
$25 was consistently associated with abnormal DSE, except
in individuals with indeterminate tests (Tables 3 and 4).
Alternately, a score of ,25 was associated with abnormal
DSE in only 5 women.
Dobutamine stress echocardiography was interpreted as
normal in 54 of the 67 women with ,50% coronary
narrowing, yielding a specificity of 80.6%. Nine of these 54
women had indeterminate studies. Wall motion abnormal-
ities in four occurred at peak stress and were confined to
basal inferior and basal inferior septal segments (2 subjects),
apical inferior and apical septal segments (1 subject) and
midanterior segment (1 subject).
Electrocardiographic analysis. At peak dobutamine infu-
sion rate, ECGs demonstrated ischemic type $1-mm ST
depression in 10/92 (13%) women. Of the 25 women with
$50% coronary narrowing, six developed $1-mm ST
segment depression during stress (sensitivity 24%); 2/9 with
$70% narrowing showed ST segment depression (22.2%).
In the 67 women with ,50% narrowing by ANGIO, six
showed ischemic ST segment changes, yielding a specificity
of 91%.
Comparisons among women with normal, abnormal or
indeterminate DSE. Analysis of findings among subjects
with normal, abnormal or indeterminate DSE revealed
lower peak heart rate in women with abnormal DSE and
more frequent use of beta-blockers among those with
abnormal or indeterminate studies (Table 4). The most
frequent reasons for termination of DSE in the 14 patients
with indeterminate studies were chest pain (in five patients,
35.7%) and hypertension (in four patients, 28.6%). Studies
were terminated in the other five patients because of
hypotension, severe dyspnea or ventricular tachycardia dur-
ing maximum infusion rate.
Findings of exercise treadmill stress testing (ETT). Ex-
ercise treadmill stress testing was performed in 57 of the 92
women with DSE. Of these, 12 had ST segment changes
considered positive for ischemia; two of these 12 women also
had wall motion abnormalities during DSE, but 10 were
normal. Exercise treadmill stress testing in the remaining 45
women was normal; 39 of these 45 also had normal DSE, and
6 showed wall motion abnormalities. No significant correlation
was found between ETT and DSE findings (p 5 0.5).
Compared to quantitative coronary angiography, sensitivity of
ETT (using ST segment criteria) for detection of coronary
stenosis $50% was 25%; specificity was 80%.
Table 3. Findings in Women With Significant Angiographic
Coronary Disease and Normal or Indeterminate Dobutamine
Stress Echocardiography
ID No. Results of DSE
Angiography
Findings,
No. (Vessels)
>50% stenosis
Angiography
Severity
Score*
30007 Normal 1 (rca) 16.25
30015 Normal 1 (lad) 19.50
30018 Normal 1 (lcx) 11.25
30020 Normal 2 (lad, lcx)† 14.75
30021 Normal 1 (lad)† 9.00
30059 Normal 1 (lad) 16.00
30068 Normal 1 (lad)† 24.25
30074 Normal 1 (rca)† 14.50
30094 Normal 1 (rca)† 8.75
30125 Normal (3 lad, lcx, rca)† 20.50
30003 Indeterminate 2 (lad, rca) 25.50
30047 Indeterminate 2 (lad, rca)† 26.00
30055 Indeterminate 2 (lad, rca) 34.50
30082 Indeterminate 2 (lm)† 21.00
30130 Indeterminate 1 (lad)† 12.25
*Larger score is indicative of more extensive disease; see text for details. †Coronary
stenosis ,70%.
Abbreviations as in Table 2.
Table 4. Comparisons Among Women With Normal, Abnormal and Indeterminate
Dobutamine Stress Echocardioraphy
Normal
(n 5 64)
Abnormal
(n 5 14)
Indeterminate
(n 5 14) p Value
Age (yr) 57.1 6 10.5 59.4 6 9.1 57.3 6 9.5 0.68
Baseline HR (bpm) 72.4 6 12.1 74.5 6 15.2 66.3 6 15.0 0.41
Baseline SBP (mm Hg) 145.4 6 24.8 138.1 6 30.1 161.1 6 28.8 0.08
Peak HR (mm Hg) 141.0 6 11.3 127.8 6 18.6 98.4 6 21.3 —
Peak SBP (mm Hg) 164.8 6 30.1 162.7 6 40.2 186.7 6 43.9 0.15
Max dose (mg/kg/min) 33.3 6 7.8 30.0 6 9.6 29.1 6 14.0 0.46
Atropine (number, %) 19 (29.7%) 2 (14.3%) 1 (7.0%) 0.14
Beta-blocker (number, %) 10 (15.6%) 5/12 (41.7%) 5 (35.7%) 0.05
Number CAD risk factors 3.8 6 1.4 4.5 6 1.7 5.1 6 1.1 0.0084
Angiography severity score 7.8 6 4.3 34.4 6 21.8 12.9 6 9.7 0.0001
CAD 5 coronary artery disease; HR 5 heart rate; Max dose 5 maximum rate of dobutamine infusion; SBP 5 systolic blood pressure.
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DISCUSSION
Dobutamine stress echocardiography has been applied to
large numbers of subjects with known or suspected CAD
with reported sensitivities ranging from 72% to 95%, and
specificities from 77% to 97% (13–23). Discrepancies
among these studies have generally been attributed to
differences in patient populations with regard to prevalence
of CAD and inclusion of patients with previous myocardial
infarction. However, nearly every study comprises predom-
inantly male subjects, and little is known about the effect of
gender on these findings.
Major findings of the present study. The present investi-
gation reveals several important observations. First, in a
cohort of women evaluated for chest pain and multiple risk
factors for CAD, angiographic evidence of significant CAD
was present in only 27%. Moreover, 40% of these women
had important stenosis in only one vessel. Dobutamine
stress echocardiography applied to this population showed
an overall sensitivity of 40%. However, in women with
multivessel stenosis, and excluding those with indeterminate
studies, sensitivity of DSE was 81.8%, similar to findings in
predominantly male cohorts (13–15,17,22).
Comparison with previous studies. Noninvasive testing
for CAD in women has generally been hampered by poor
specificity (2,5,24). Previous observations, although limited,
suggest that DSE shares this limitation (25,26). In a study
by Bach et al. of patients with false positive DSE, women
were more likely to have false positive studies, accounting
for 72% of the group (25). Women had a fourfold incidence
of false positive studies, nearly 20% compared with only 5%
in men. This differs substantially from the findings of our
study which demonstrate a very low false positive rate and
specificity of approximately 81% in patients without angio-
graphic evidence of significant disease. This discrepancy
likely relates to methodologic differences. In particular,
postcatheterization referral biases observed in prior studies
in which only abnormal DSE responses are referred for
ANGIO artificially deflate test specificity. The WISE study
design, conversely, in which all subjects underwent DSE
and ANGIO, eliminates this bias. In addition, the low
overall prevalence of abnormal DSE and significant coro-
nary artery narrowing likely contributed to the high speci-
ficity observed in this study.
Sensitivity of DSE in women. The explanation for the
poor overall sensitivity of DSE in this group of women also
relates in part to the relatively low overall prevalence of
severe coronary artery narrowing. Previous reports have
included cohorts with from 42% to 87% prevalence of
angiographic disease (13,16,17,22,27,28). For example, El-
hendy et al. evaluated the accuracy of DSE in women (28)
and found overall sensitivity of 76%. Prevalence of CAD in
the cohort of women studied was 65%, substantially higher
than the present investigation, and over one half of women
studied had prior myocardial infarction. The lower preva-
lence of coronary stenosis in WISE patients may be a
consequence of several factors. Most patients had no previ-
ously documented myocardial infarction, and individuals
with unstable symptoms were excluded from study. Also,
the intent of our study was to evaluate a broadly represen-
tative cohort of women undergoing evaluation for suspected
myocardial ischemia, as well as to include other possible
causes for ischemia such as microvascular dysfunction. As a
consequence, the cohort of women in this study may indeed
reflect a more accurate representation of women being
evaluated for chest pain. Nonetheless, our cohort of women
had clinical indication for coronary angiography based on
the presenting symptoms and prevalence of risk factors.
Findings in these patients may not be applicable to other
groups of women with chest pain syndromes without
clinical indication for coronary angiography, and lower
sensitivity of DSE might be expected in such individuals.
Another contributing factor to the low overall sensitivity
of DSE in the WISE study relates to 40% prevalence of
single-vessel involvement in women with epicardial coro-
nary artery stenosis. The lower sensitivity of DSE for
detection of single-vessel stenosis has been reported by most
previous investigations and has ranged from 50% to 80%
(16,21–23,29). Moreover, myocardial ischemia is influenced
by factors other than luminal narrowing, such as lesion
morphology and collateral circulation. The relation of DSE
findings to angiography severity score used in the present
study underscores this more complex relationship between
inducible myocardial ischemia and lesion description. In the
present study, sensitivity was lower in women with single-
vessel stenosis and low angiographic severity score, poten-
tially representing individuals with low risk for inducible
myocardial ischemia of sufficient severity to result in wall
motion abnormalities. For example, an angiography severity
score less than 25 was rarely associated with inducible
myocardial ischemia, whereas a score $35 was invariably
associated with abnormal wall motion.
Adverse effects and indeterminate DSE. Few patients
(15%) did not achieve target heart rates during DSE. These
“indeterminate” tests were due largely to premature termi-
nation of DSE because of intolerable symptoms of chest
pain or dyspnea, or important cardiovascular side effects
including hypertension and hypotension. Of note, a hyper-
tensive response to dobutamine infusion in one third of the
prematurely terminated studies was consistently observed
only in women with history of hypertension, and was likely
exacerbated by the routine cessation of medication before
testing. These findings are comparable to those of previous
investigations (22,30–32). In a study of over 3,000 patients
(32), Secknus and Marwick reported premature termination
of DSE in 15% of patients, most of these for cardiovascular
side effects. In the present study, the presence of severe
coronary artery stenosis in one third of women with inde-
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terminate DSE underscores the need for further evaluation
and testing in these patients with inconclusive findings.
Conclusions. In summary, DSE reliably detects multives-
sel stenosis in women with suspected CAD. However, DSE
is usually negative in women with single-vessel disease, and
in the larger subset of women with chest pain and without
angiographic coronary stenosis. The findings of the present
study constitute pilot phase data from the WISE study and
require confirmation in the larger group of women subse-
quently enrolled. Protocols performed during the ensuing
years of the WISE study are expected to improve diagnostic
accuracy in women with single-vessel disease. In particular,
because the low overall sensitivity in single-vessel stenosis
results in part from smaller stress-induced wall motion
abnormalities, the efficacy of contrast echocardiography for
improved endocardial visualization of wall motion will be
assessed in this cohort. With regard to the substantial
number of women with chest pain but without epicardial
coronary artery stenosis, a protocol testing the relation
between abnormal coronary flow reserve and myocardial
ischemia using phosphorus-31 nuclear magnetic resonance
spectroscopy is in progress (33).
Reprint requests and correspondence: Dr. Jannet F. Lewis, c/o
WISE Coordinating Center, University of Pittsburgh, 127 Parran
Hall, 130 DeSoto St., Pittsburgh, Pennsylvania 15261.
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